Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy

European Urology

Volumn 72, Issue 5, 2017, Pages 712-735

  Schroeck, Florian Rudolf ^a,b,c   Jacobs, Bruce L ^d   Bhayani, Sam B ^e   Nguyen, Paul L ^f   Penson, David ^g,h   Hu, Jim ⁱ  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

ⁱ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Cost; Cost effectiveness; New technology; Prostate cancer; Systematic review

Indexed keywords

CANCER RADIOTHERAPY; CANCER SURGERY; CONFORMAL RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; ROBOT-ASSISTED PROSTATECTOMY; SYSTEMATIC REVIEW; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; LAPAROSCOPY; MALE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; ROBOTIC SURGICAL PROCEDURE; TIME FACTOR; TREATMENT OUTCOME;

COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; LAPAROSCOPY; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTON THERAPY; QUALITY OF LIFE; RADIOTHERAPY, INTENSITY-MODULATED; ROBOTIC SURGICAL PROCEDURES; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 85016490398     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.03.028     Document Type: Review

References (85)

1. Jacobs, B.L., Zhang, Y., Skolarus, T.A., Hollenbeck, B.K., Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood) 31 (2012), 750–759.
2. Hu, J.C., O'Malley, P., Chughtai, B., et al. Comparative effectiveness of cancer control and survival after robot-assisted versus open radical prostatectomy. J Urol 197 (2017), 115–121.
3. Mahal, B.A., Chen, Y.-W., Efstathiou, J.A., et al. National trends and determinants of proton therapy use for prostate cancer: a National Cancer Data Base study. Cancer 122 (2016), 1505–1512.
4. Yu, J.B., Soulos, P.R., Herrin, J., et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 105 (2013), 25–32.
5. Pollack, A., Hospitals look to nuclear tool to fight cancer. 2007, New York Times.
6. Barbash, G.I., Glied, S.A., New technology and health care costs—the case of robot-assisted surgery. N Engl J Med 363 (2010), 701–704.
7. Efstathiou, J.A., Gray, P.J., Zietman, A.L., Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer 108 (2013), 1225–1230.
8. Lotan, Y., Cadeddu, J., Gettman, M., The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot assisted techniques. J Urol 172 (2004), 1431–1435.
9. Tewari, A., Sooriakumaran, P., Bloch, D.A., Seshadri-Kreaden, U., Hebert, A.E., Wiklund, P., Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 62 (2012), 1–15.
10. Hu, J.C., Gu, X., Lipsitz, S.R., et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302 (2009), 1557–1564.
11. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100.
12. Shamseer, L., Moher, D., Clarke, M., et al. Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 349, 2015, g7647.
13. Carande-Kulis, V.G., Maciosek, M.V., Briss, P.A., et al. Methods for systematic reviews of economic evaluations for the guide to community preventive services. Am J Prev Med 18 (2000), 75–91.
14. Morrison, A., Polisena, J., Husereau, D., et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28 (2012), 138–144.
15. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in healthcare. 2009, Centre for Reviews and Dissemination, York University York NHS.
16. Balshem, H., Helfand, M., Schünemann, H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
17. Kind, P., Lafata, J.E., Matuszewski, K., Raisch, D., The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health 12 (2009), S27–S30.
18. Ubel, P.A., Hirth, R.A., Chernew, M.E., Fendrick, A.M., What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med, 163, 2003, 1637.
19. Marseille, E., Larson, B., Kazi, D.S., et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 93 (2015), 118–124.
20. Shiroiwa, T., Sung, Y.-K., Fukuda, T., Lang, H.-C., Bae, S.-C., Tsutani, K., International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 19 (2010), 422–437.
21. Mouraviev, V., Nosnik, I., Sun, L., et al. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology 69 (2007), 311–314.
22. Riley, G.F., Administrative and claims records as sources of health care cost data. Med Care 47 (2009), S51–S55.
23. Leow, J.J., Chang, S.L., Meyer, C.P., et al. Robot-assisted versus open radical prostatectomy: a contemporary analysis of an all-payer discharge database. Eur Urol 70 (2016), 837–845.
24. Basto, M., Sathianathen, N., TeMarvelde, L., et al. Patterns-of-care and health economic analysis of robot-assisted radical prostatectomy in the Australian public health system. BJU Int 117 (2016), 930–939.
25. Scales, C.D. Jr., Jones, P.J., Eisenstein, E.L., Preminger, G.M., Albala, D.M., Local cost structures and the economics of robot assisted radical prostatectomy. J Urol 174 (2005), 2323–2329.
26. Abdollah, F., Budäus, L., Sun, M., et al. Impact of caseload on total hospital charges: a direct comparison between minimally invasive and open radical prostatectomy—a population based study. J Urol 185 (2011), 855–861.
27. Niklas, C., Saar, M., Berg, B., et al. da Vinci and open radical prostatectomy: comparison of clinical outcomes and analysis of insurance costs. Urol Int 96 (2016), 287–294.
28. Hughes, D., Camp, C., O'Hara, J., Adshead, J., Health resource use after robot-assisted surgery vs open and conventional laparoscopic techniques in oncology: analysis of English secondary care data for radical prostatectomy and partial nephrectomy. BJU Int 117 (2016), 940–947.
29. Bijlani, A., Hebert, A.E., Davitian, M., et al. A multidimensional analysis of prostate surgery costs in the united states: robotic-assisted versus retropubic radical prostatectomy. Value Health 19 (2016), 391–403.
30. Miller, D.C., Gust, C., Dimick, J.B., Birkmeyer, N., Skinner, J., Birkmeyer, J.D., Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. Health Aff Proj Hope 30 (2011), 2107–2115.
31. Shih Y-CT, Ward, J.F., Pettaway, C.A., et al. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health 15 (2012), 367–375.
32. Epstein, A.J., Groeneveld, P.W., Harhay, M.O., Yang, F., Polsky, D., Impact of minimally invasive surgery on medical spending and employee absenteeism. JAMA Surg 148 (2013), 641–647.
33. Kim, S.P., Gross, C.P., Smaldone, M.C., et al. Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population. Prostate Cancer Prostatic Dis 18 (2015), 13–17.
34. Bai, G., Anderson, G.F., Extreme markup: the fifty US hospitals with the highest charge-to-cost ratios. Health Aff (Millwood) 34 (2015), 922–928.
35. Cooperberg, M.R., Ramakrishna, N.R., Duff, S.B., et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int 111 (2013), 437–450.
36. Eldefrawy, A., Katkoori, D., Abramowitz, M., Soloway, M.S., Manoharan, M., Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol 31 (2013), 576–580.
37. O'Malley, S.P., Jordan, E., Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: The case for remotely assisted radical prostatectomy. Int J Technol Assess Health Care 23 (2007), 286–291.
38. Hohwü, L., Borre, M., Ehlers, L., Venborg Pedersen, K., A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy. J Med Econ 14 (2011), 403–409.
39. Nguyen, P.L., Gu, X., Lipsitz, S.R., et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29 (2011), 1517–1524.
40. Yong, J.H.E., Beca, J., McGowan, T., Bremner, K.E., Warde, P., Hoch, J.S., Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. Clin Oncol 24 (2012), 521–531.
41. Konski, A., Cost-effectiveness of intensity-modulated radiation therapy. Expert Rev Pharmacoecon Outcomes Res 5 (2005), 137–140.
42. Yong, J.H.E., McGowan, T., Redmond-Misner, R., et al. Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario. Curr Oncol 23 (2016), e228–e238.
43. Zemplényi A t., Kaló Z, Kovács G, et al. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl). In press. http://dx.doi.org/10.1111/ecc.12430.
44. Carter, H.E., Martin, A., Schofield, D., et al. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiother Oncol 112 (2014), 187–193.
45. Konski, A., Speier, W., Hanlon, A., Beck, J.R., Pollack, A., Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 25 (2007), 3603–3608.
46. Lundkvist, J., Ekman, M., Ericsson, S.R., Jönsson, B., Glimelius, B., Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol 44 (2005), 850–861.
47. Yaxley, J.W., Coughlin, G.D., Chambers, S.K., et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 388 (2016), 1057–1066.
48. Novara, G., Ficarra, V., Mocellin, S., et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 62 (2012), 382–404.
49. Ficarra, V., Novara, G., Rosen, R.C., et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62 (2012), 405–417.
50. Ficarra, V., Novara, G., Ahlering, T.E., et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 62 (2012), 418–430.
51. Yu, T., Zhang, Q., Zheng, T., et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One, 11, 2016, e0154499.
52. Hall, E.J., Wuu C-S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol 56 (2003), 83–88.
53. Proton therapy vs. IMRT for low or intermediate risk prostate cancer PARTIQoL 2016. https://clinicaltrials.gov/ct2/show/NCT01617161.
54. Moon, D.H., Efstathiou, J.A., Chen, R.C., What is the best way to radiate the prostate in 2016?. Urol Oncol 35 (2017), 59–68.
55. Fang, P., Mick, R., Deville, C., et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer 121 (2015), 1118–1127.
56. Gray, P.J., Paly, J.J., Yeap, B.Y., et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119 (2013), 1729–1735.
57. Hoppe, B.S., Michalski, J.M., Mendenhall, N.P., et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120 (2014), 1076–1082.
58. Sheets, N.C., Goldin, G.H., Meyer, A-M., et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307 (2012), 1611–1620.
59. Chen, C., Ackerly, D.C., Beyond ACOs and bundled payments: Medicare's shift toward accountability in fee-for-service. JAMA, 311, 2014, 673.
60. Porter, M.E., What Is value in health care?. N Engl J Med 363 (2010), 2477–2481.
61. Laviana, A.A., Ilg, A.M., Veruttipong, D., et al. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer: TDABC and low-risk prostate cancer. Cancer 122 (2016), 447–455.
62. Gandaglia, G., Bray, F., Cooperberg, M.R., et al. Prostate cancer registries: current status and future directions. Eur Urol 69 (2016), 998–1012.
63. Lotan, Y., Bolenz, C., Gupta, A., et al. The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. BJU Int 105 (2010), 1531–1535.
64. Bolenz, C., Gupta, A., Hotze, T., et al. The influence of body mass index on the cost of radical prostatectomy for prostate cancer. BJU Int 106 (2010), 1188–1193.
65. Kim, S.P., Shah, N.D., Karnes, R.J., et al. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol 64 (2013), 11–16.
66. Yu, H., Hevelone, N.D., Lipsitz, S.R., Kowalczyk, K.J., Hu, J.C., Use, costs and comparative effectiveness of robotic assisted, laparoscopic and open urological surgery. J Urol 187 (2012), 1392–1398.
67. Hall, R.M., Linklater, N., Coughlin, G., Robotic and open radical prostatectomy in the public health sector: cost comparison. ANZ J Surg 84 (2014), 477–480.
68. Tomaszewski, J.J., Matchett, J.C., Davies, B.J., Jackman, S.V., Hrebinko, R.L., Nelson, J.B., Comparative hospital cost-analysis of open and robotic-assisted radical prostatectomy. Urology 80 (2012), 126–129.
69. Chang, S.L., Kibel, A.S., Brooks, J.D., Chung, B.I., The impact of robotic surgery on the surgical management of prostate cancer in the USA. BJU Int 115 (2015), 929–936.
70. Chughtai, B., Scherr, D., Del Pizzo, J., et al. National trends and cost of minimally invasive surgery in urology. Urol Pract 2 (2015), 49–54.
71. Fabbro, E., Crivellaro, S., DalleFratte, C.F., et al. Robot-assisted laparoscopic prostatectomy: an economic analysis for decision-making in a university hospital of Northern Italy. Epidemiol Biostat Public Health 12 (2014), 1–9.
72. Faiena, I., Dombrovskiy, V.Y., Modi, P.K., et al. Regional cost variations of robot-assisted radical prostatectomy compared with open radical prostatectomy. Clin Genitourin Cancer 13 (2015), 447–452.
73. Yanamadala, S., Chung, B.I., Hernandez-Boussard, T.M., Robot-assisted versus open radical prostatectomy utilization in hospitals offering robotics. Can J Urol 23 (2016), 8279–8284.
74. Gagnon, L.-O., Goldenberg, S.L., Lynch, K., Hurtado, A., Gleave, M.E., Comparison of open and robotic-assisted prostatectomy: the University of British Columbia experience. Can Urol Assoc J 8 (2014), 92–97.
75. Burgess, S.V., Atug, F., Castle, E.P., Davis, R., Thomas, R., Cost analysis of radical retropubic, perineal, and robotic prostatectomy. J Endourol 20 (2006), 827–830.
76. Prasad, S.M., Gu, X., Lavelle, R., Lipsitz, S.R., Hu, J.C., Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy. J Urol 185 (2011), 111–115.
77. Lowrance, W.T., Eastham, J.A., Yee, D.S., et al. Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis. Cancer 118 (2012), 3079–3086.
78. Hofer, M.D., Meeks, J.J., Cashy, J., Kundu, S., Zhao, L.C., Impact of increasing prevalence of minimally invasive prostatectomy on open prostatectomy observed in the national inpatient sample and national surgical quality improvement program. J Endourol 27 (2013), 102–107.
79. Anderson, J.E., Chang, D.C., Parsons, J.K., Talamini, M.A., The first national examination of outcomes and trends in robotic surgery in the United States. J Am Coll Surg 215 (2012), 107–114 discussion 114-6.
80. Gandaglia, G., Sammon, J.D., Chang, S.L., et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol 32 (2014), 1419–1426.
81. Hyams, E.S., Mullins, J.K., Pierorazio, P.M., Partin, A.W., Allaf, M.E., Matlaga, B.R., Impact of robotic technique and surgical volume on the cost of radical prostatectomy. J Endourol 27 (2013), 298–303.
82. Sugihara, T., Yasunaga, H., Horiguchi, H., et al. Robot-assisted versus other types of radical prostatectomy: population-based safety and cost comparison in Japan, 2012-2013. Cancer Sci 105 (2014), 1421–1426.
83. Konski, A., Watkins-Bruner, D., Feigenberg, S., et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol 66 (2006), 408–415.
84. Hummel, S.R., Stevenson, M.D., Simpson, E.L., Staffurth, J., A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clin Oncol 24 (2012), e159–e167.
85. Menon, M., Shrivastava, A., Tewari, A., Laparoscopic radical prostatectomy: conventional and robotic. Urology 66 (2005), 101–104, 10.1016/j.urology.2005.06.008.